DCM
YMAB

Driehaus Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Driehaus Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-297,252
Closed -$4.29M – 413
2022
Q3 		$4.29M Buy
+297,252
New +$4.92M 0.06% 283
2021
Q2 		– Sell
-352,717
Closed -$10.7M – 534
2021
Q1 		$10.7M Buy
352,717
+67,849
+24% +$2.78M 0.16% 196
2020
Q4 		$14.1M Sell
284,868
-13,345
-4% -$617K 0.23% 125
2020
Q3 		$11.4M Sell
298,213
-35,647
-11% -$1.42M 0.24% 120
2020
Q2 		$14.4M Sell
333,860
-110,576
-25% -$4.18M 0.35% 90
2020
Q1 		$11.6M Sell
444,436
-2,806
-0.6% -$81.5K 0.39% 71
2019
Q4 		$14M Buy
447,242
+240,153
+116% +$7.11M 0.37% 74
2019
Q3 		$5.4M Buy
207,089
+7,246
+4% +$185K 0.18% 145
2019
Q2 		$4.57M Buy
+199,843
New +$4.59M 0.14% 171

Other funds holding YMAB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Driehaus Capital Management's YMAB Position: Q4 2022 in Review

Driehaus Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q4 2022, closing a stake of 297,252 shares — an estimated $4.29M sold.

Driehaus Capital Management first reported a position in YMAB in Q2 2019 and held it in 9 quarters. The position peaked at $14.4M in Q2 2020. 91 funds tracked by Wall St. Rank hold YMAB as of Q4 2022.

  • Driehaus Capital Management reported no remaining Y-mAbs Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Driehaus Capital Management sold 297,252 Y-mAbs Therapeutics shares in Q4 2022, an estimated $4.29M.
  • Driehaus Capital Management first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 9 quarters.
  • Driehaus Capital Management's Y-mAbs Therapeutics position peaked at $14.4M in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q4 2022.

Based on Driehaus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.